Activity

It may also interfere with other medications that contain opiates such as certain cough and cold medications, antidiarrheal medications, and some analgesics (pain medications). Report any changes in vision to your doctor as soon as possible while you are taking this medication. If you have glaucoma, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed. If you or a family member has been diagnosed with Brugada syndrome, talk to your doctor about this before you start taking naltrexone – bupropion. Although most of the side effects listed below don’t happen very often, they could lead to serious problems if you do not seek medical attention.

However, some of these adverse events occurred in patients taking bupropion who continued to smoke. Prescriptions for CONTRAVE should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose. Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient’s presenting symptoms.

In this trial, the achievement of at least a 5% reduction in body weight from baseline occurred more frequently for patients treated with CONTRAVE 32 mg/360 mg compared with placebo (42% vs 17%; Table 6). In the 56-week COR-I trial, the mean change in body weight was -5.4% among patients assigned to CONTRAVE 32 mg/360 mg compared with -1.3% among patients assigned to placebo (Intent-To-Treat ITT population), as shown in Table 6 and Figure 1. The co-primary endpoints were percent change from baseline body weight and the proportion of patients achieving at least a 5% reduction in body weight.

The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. This warning applies to CONTRAVE because one of its components, bupropion, is a member of an antidepressant class. It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. In rodents, it has been shown to increase locomotor activity, elicit a mild stereotyped behavioral response, and increased rates of responding in several schedule-controlled behavior paradigms.

You may find it necessary to monitor your blood sugar more frequently while using this medication. These factors may affect how you should use this medication. Check with your doctor if you notice any symptom that worries you while you are taking this medication. Some people may experience side effects other than those listed. Your pharmacist may be able to advise you on managing side effects.

Brian’s journey included numerous diets, exercise, and trying a GLP-1 medication before he found CONTRAVE. “I never thought I’d get back to this weight.”

The exact neurochemical effects of CONTRAVE leading to weight loss are not fully understood. The exact neurochemical effects of CONTRAVEleading to weight loss are not fully understood. Talk with alcosystems to find out if you are at risk for angle-closure glaucoma and to get treatment to prevent it if you are at risk.

There was no evidence of carcinogenicity in a two-year dietary study with naltrexone in male and female mice.Lifetime carcinogenicity studies of bupropion were performed in rats and mice at doses up to 300 and 150 mg/kg/day, respectively. Safety margins were estimated using body surface area exposure (mg/m²) based on a body weight of 100 kg.In a two-year carcinogenicity study in rats with naltrexone, there were small increases in the numbers of testicular mesotheliomas in males and tumors of vascular origin in males and females. Decreases in medication doses for antidiabetic medications which are non-glucose-dependent should be considered to mitigate the risk of hypoglycemia. Use of CONTRAVE should be discontinued in the event of symptoms and/or signs of acute hepatitis.In CONTRAVE clinical trials, there were no cases of elevated transaminases greater than three times the upper limit of normal (ULN) in conjunction with an increase in bilirubin greater than two times ULN.Bupropion, a component of CONTRAVE, is a drug used for the treatment of depression. These symptoms may resemble serum sickness.Cases of hepatitis and clinically significant liver dysfunction were observed in association with naltrexone exposure during naltrexone clinical trials and in postmarketing reports for patients using naltrexone. The clinical significance of the increases in blood pressure and heart rate observed with CONTRAVE treatment is unclear, especially for patients with cardiac and cerebrovascular disease, since patients with a history of myocardial infarction or stroke in the previous 6 months, life-threatening arrhythmias, or congestive heart failure were excluded from CONTRAVE clinical trials.

gastouderbureauheuvelrug should be warned of the risk of hepatic injury and advised to seek medical attention if they experience symptoms of acute hepatitis. Instruct patients to discontinue CONTRAVE and consult a healthcare provider if they develop an allergic or anaphylactoid/anaphylactic reaction (e.g., skin rash, pruritus, hives, chest pain, edema, or shortness of breath) during treatment. Therefore, the maximum recommended daily maintenance dose of CONTRAVE is two tablets (one tablet each morning and evening) in patients with moderate hepatic impairment. Therefore, the maximum recommended daily maintenance dose for CONTRAVE is two tablets (one tablet each morning and evening) in patients with moderate or severe renal impairment. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.